State of Wyoming Has $515,000 Stake in OraSure Technologies, Inc. (NASDAQ:OSUR)

State of Wyoming trimmed its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 19.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 142,567 shares of the medical instruments supplier’s stock after selling 35,433 shares during the period. State of Wyoming’s holdings in OraSure Technologies were worth $515,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in OraSure Technologies by 202.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 5,234 shares in the last quarter. Causeway Capital Management LLC acquired a new stake in OraSure Technologies during the fourth quarter worth about $36,000. Raymond James Financial Inc. acquired a new stake in OraSure Technologies during the fourth quarter worth about $37,000. Boothbay Fund Management LLC acquired a new stake in OraSure Technologies during the fourth quarter worth about $42,000. Finally, Gotham Asset Management LLC acquired a new stake in OraSure Technologies during the fourth quarter worth about $43,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Trading Up 8.2%

OSUR opened at $2.63 on Tuesday. The company’s 50 day moving average is $3.06 and its 200-day moving average is $3.55. OraSure Technologies, Inc. has a 1-year low of $2.36 and a 1-year high of $5.08. The company has a market cap of $196.72 million, a P/E ratio of 17.53 and a beta of 0.42.

OraSure Technologies announced that its board has approved a stock repurchase program on Monday, March 24th that allows the company to buyback $40.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 15.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity

In other OraSure Technologies news, CEO Manner Carrie Eglinton bought 78,625 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average cost of $3.15 per share, for a total transaction of $247,668.75. Following the transaction, the chief executive officer now directly owns 1,259,664 shares in the company, valued at approximately $3,967,941.60. This represents a 6.66% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kenneth J. Mcgrath bought 64,000 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average price of $3.15 per share, for a total transaction of $201,600.00. Following the completion of the transaction, the chief financial officer now owns 371,013 shares in the company, valued at $1,168,690.95. This trade represents a 20.85% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 190,284 shares of company stock worth $600,348. Corporate insiders own 3.90% of the company’s stock.

Analyst Ratings Changes

OSUR has been the topic of a number of research analyst reports. Evercore ISI restated an “in-line” rating and issued a $3.00 price target on shares of OraSure Technologies in a research note on Monday. StockNews.com upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Saturday.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.